Geoffrey Cumming has over 20 years of experience in senior roles within the global healthcare and biotechnology sector.
As managing director of Roche Diagnostic Systems (Oceania), Mr Cumming transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. As managing director and chief executive of Biosceptre International, he designed and secured key funding arrangements through a range of capital raising initiatives including large government grants, partnering and co-development deals. Mr Cumming was also managing director and chief executive of Anteo Diagnostics, chair of Sienna Cancer Diagnostics, and non-executive director of ASX-listed Medical Australia.
